Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 30, 2015, reports the completion of a major acquisition by Perrigo Company plc (the "Company"). The transaction involves the acquisition of Omega Pharma Invest NV ("Omega"), a Belgian pharmaceutical company.
Key Financial Metrics and Transaction Details
The Company acquired 685,348,257 shares of Omega, representing 95.77% of its issued and outstanding share capital. The remaining 30,243,983 shares were held by Omega as treasury shares.
- Cash Consideration: EUR 1,845,983,131 paid to sellers, plus EUR 62,479,261 in interest accrued from September 30, 2014, to the completion date.
- Non-Cash Consideration: Issuance of 5,397,711 shares of the Company to seller Alychlo NV.
- Assumed Debt: The Company assumed all outstanding indebtedness of Omega and its subsidiaries, including:
- EUR 135,043,889 of 5.1045% senior notes due 2023.
- USD 20,000,000 (approx. EUR 16,247,000) of 6.19% senior notes due 2016.
- EUR 600,000,000 in retail bonds (EUR 300M due 2017, EUR 180M due 2017, EUR 120M due 2019).
- Approximately EUR 500,000,000 available under a revolving credit facility (terminated upon closing).
- Approximately EUR 50,000,000 available under overdraft facilities.
The filing text does not provide specific revenue, profit, cash flow, or margin figures for the Company or Omega for this period.
Material Changes and Post-Closing Actions
Upon completion, Omega issued a notice of termination for its revolving credit facility. Additionally, a change of control offer was issued for the 2016 Notes, 2023 Notes, and Retail Notes. The transaction significantly alters the Company's capital structure through the assumption of substantial debt and the issuance of equity.
Management Commentary, Risks, and Contingencies
The Share Purchase Agreement includes specific covenants regarding competition and solicitation:
- Non-Compete: Alychlo is subject to a three-year non-compete in Europe and Belgium. Marc Coucke is subject to a non-compete until the later of five years from completion or three years after ceasing employment/association with the Company.
- No-Solicit: Sellers are subject to a two-year no-solicit agreement.
- Lock-Up: The non-cash consideration shares issued to Alychlo are subject to a lock-up agreement, though registration rights were granted.
Key Facts for Investor Verification
- Verify the total enterprise value of the acquisition including the assumed debt load of approximately EUR 891 million in bonds and notes plus overdraft facilities.
- Confirm the status of the change of control offers for Omega's debt instruments and whether they were accepted by bondholders.
- Review the impact of the 5,397,711 new shares issued to Alychlo on existing shareholder dilution.
- Monitor the integration of Omega's operations and the execution of the non-compete covenants.